



International Science Group

ISG-KONF.COM

XIX

**INTERNATIONAL SCIENTIFIC
AND PRACTICAL CONFERENCE
«CURRENT PROBLEMS OF THE DEVELOPMENT OF
SCIENCE: TRENDS AND INNOVATIONS»**

Oslo, Norway

May 13 – 16, 2025

ISBN 979-8-89692-714-3

DOI 10.46299/ISG.2025.1.19

34.	Романенко С.В., Марчук І.А. СУЧАСНІ ПІДХОДИ ДО СТРАТЕГІЧНОГО УПРАВЛІННЯ МЕДИЧНИМИ ЗАКЛАДАМИ В УМОВАХ РИНКОВОЇ КОНКУРЕНЦІЇ	194
MEDICINE		
35.	Baikuatov A.K., Aliyeva V.K., Suleimenova M.D., Nurkassymova A.G., Bogoslavskaya D. MODERN APPROACHES TO THE DIAGNOSIS AND TREATMENT OF BIPOLAR DISORDER: ANALYSIS OF NEW METHODS AND PSYCHOTHERAPEUTIC STRATEGIES	198
36.	Khlananova L., Yaremenko L., Grabovyi O., Nevmerzhytska N. MEDICAL EDUCATION: THE ROLE OF HISTOLOGY IN THE DEVELOPMENT OF STUDENTS' CLINICAL THINKING	204
37.	Kurbanali R., Saparbek A.R., Begim Z.T., Orazbay A.O., Airikh E.S. RARE ENDOCRINE TUMORS: FEATURES OF DIAGNOSIS AND TREATMENT OF PHEOCHROMOCYTOMA	206
38.	Vizir V., Demidenko O., Sadomov A., Buriak V., Prykhodko I. MANAGEMENT OF REPRODUCTIVE WOMEN WITH ARTERIAL HYPERTENSION	214
39.	Zdolnik I., Bulda V., Savchuk A. OVERWEIGHT, OBESITY AND PREDIABETES IN PATIENTS WITH ARTERIAL HYPERTENSION: EARLY DETECTION AND PREVENTION	217
40.	Імрані А.Д., Ослам Є.Ю., Зайцева О.В. ЛАЗЕРНІ ТЕХНОЛОГІЇ В ДІАГНОСТИЦІ ТА ЛІКУВАННІ: СУЧАСНИЙ МЕДИЧНИЙ ПІДХІД	221
41.	Бунятян Х.А., Хотімська Ю.В., Щербина І.М., Лавренюк Я.В. МОРФОЛОГІЧНА ХАРАКТЕРИСТИКА ТКАНИН ЗУБА ТВАРИН ПІСЛЯ ПРЯМОГО ПОКРИТТЯ ПУЛЬПИ ЗА ДОПОМОГОЮ ОДОНТОТРОПНИХ ПРЕПАРАТІВ	225
42.	Біловол А.М., Здоровець А.О., Олійник Д.І. РІВЕНЬ ОБІЗНАНОСТІ МОЛОДІ ПРИФРОНТОВИХ МІСТ УКРАЇНИ ПРО РОЗПОВСЮДЖЕНІСТЬ ТА РИЗИКИ ЗАХВОРЮВАНOSTІ НА СИФІЛІС	229

MANAGEMENT OF REPRODUCTIVE WOMEN WITH ARTERIAL HYPERTENSION

Vizir Vadym

D.Sc., Professor

Zaporizhzhia State Medical-Pharmacy University

Demidenko Olexandr

Ph.D., Associate Professor

Zaporizhzhia State Medical-Pharmacy University

Sadomov Anton

Ph.D., Associate Professor

Zaporizhzhia State Medical-Pharmacy University

Buriak Viktor

Ph.D., Associate Professor

Zaporizhzhia State Medical-Pharmacy University

Prykhodko Igor

Ph.D., Associate Professor

Zaporizhzhia State Medical-Pharmacy University

Arterial hypertension (AH) in women of reproductive age is a significant medical problem that can have serious consequences for both mother and fetus during pregnancy, as well as increase the risk of cardiovascular disease in the future [1,2]. Based on the recommendations of the European Society of Cardiology on the management of hypertension, updated guidelines for the diagnosis, risk assessment, and treatment of this category of patients should be considered, taking into account their characteristics and reproductive plans.

A comprehensive cardiovascular risk assessment should be performed, taking into account the history, risk factors (family history, smoking, dyslipidemia, obesity, diabetes), and the presence of target organ damage. In women of reproductive age with sudden onset of hypertension, severe or treatment-resistant hypertension, screening for secondary causes, including primary aldosteronism and kidney disease, should be considered. It is also important to take a history of reproductive function, contraceptive use, previous pregnancies (including preeclampsia and gestational hypertension), and plans for future pregnancies [3].

Lifestyle modification includes general recommendations, including healthy eating, regular physical activity, maintaining a healthy weight, smoking cessation, and limiting alcohol consumption. The effect of various contraceptive methods on blood pressure should also be taken into account. In particular, estrogen-containing drugs can

increase blood pressure (BP) in some women, so progestin-containing or non-hormonal methods should be preferred, especially in the presence of risk factors for hypertension [4].

The decision to initiate pharmacologic treatment depends on the level of blood pressure and overall cardiovascular risk. Pharmacologic treatment outside of pregnancy has specifics regarding the choice of antihypertensive drugs. In particular, ACEIs and ARBs are the drugs of choice for women with concomitant diabetes mellitus, chronic kidney disease, or high cardiovascular risk. However, it is important to keep in mind their teratogenicity and the need to discontinue them when planning or becoming pregnant. Beta-blockers, calcium channel blockers, and thiazide diuretics can be used with caution before and during pregnancy, taking into account individual indications. Often, a combination of two or more antihypertensive drugs is required to achieve target blood pressure levels. [4,5].

An important aspect is the implementation of follow-up. Thus, women of reproductive age with hypertension need regular medical monitoring to control blood pressure levels, evaluate the effectiveness of treatment, and identify possible complications. It is important to inform women who had hypertension during pregnancy about the increased risk of developing chronic hypertension and cardiovascular disease in the future and recommend appropriate prevention measures. It is essential to emphasize lifestyle changes and control of risk factors to prevent cardiovascular events in the long term. [6,7].

Thus, the management of hypertension in women of reproductive age is a complex task that requires an individualized approach, taking into account reproductive plans and the potential impact of treatment on pregnancy. Involvement of cardiologists, obstetricians and gynecologists, general practitioners and other specialists is important to ensure comprehensive and effective management of hypertension in women of reproductive age.

References:

1. McEvoy, J. W., McCarthy, C. P., Bruno, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. *European heart journal*, 45(38), 3912–4018. <https://doi.org/10.1093/eurheartj/ehae178>
2. Brown MA, Magee LA, Kenny LC, et al. Hypertensive disorders of pregnancy: ISSHP classification, diagnosis, and management recommendations for international practice. *Pregnancy Hypertens.* 2018;15:24-43.
3. Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). *Eur Heart J.* 2016;37(29):2315-2381.
4. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. *Eur Heart J.* 2018;39(33):3021-3104.

5. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. ESC Guidelines on the management of cardiovascular diseases during pregnancy. *Eur Heart J*. 2018;39(34):3165-3241.
6. National Institute for Health and Care Excellence (NICE). Hypertension in adults: diagnosis and management. NG136. Published: 28 August 2019.
7. Zhou Y, Zhang Y, Zhang H, et al. Association of hypertensive disorders of pregnancy with subsequent cardiovascular disease risk: a systematic review and meta-analysis of cohort studies. *BMJ*. 2021;373:n237.